Abstract: Metal complexes including a radionuclide and a compound of Formula I and Formula II are potent inhibitors of PSMA.

Abstract: A powder boronizing composition comprising: a. 0.5 to 4.5 wt % of a boron source selected from B4C, amorphous boron, calcium hexaboride, borax or mixtures thereof; b. 45.5 to 88.5 wt % of a diluent selected from SiC, alumina or mixtures thereof; c. 1.0 to 20.0 wt % of an activator selected from KBF4, ammonia chloride, cryolite or mixtures thereof; and d. 10.0 to 30.0 wt % of a sintering reduction agent selected from carbon black, graphite or mixtures thereof.

Abstract: Metal complexes including a radionuclide and a compound of Formula I and Formula II are potent inhibitors of PSMA.

Abstract: Metal complexes including a radionuclide and a compound of Formula I and Formula II are potent inhibitors of PSMA.

Abstract: A process comprising: placing a boronizing powder composition in the interior of a metal pipe comprising a first end, a second end, an inside surface and an outside surface; heating the pipe in a vessel having an interior, to a temperature from 1400° F. to 1900° F., thereby forming spent boronizing reaction gases and a borided layer on the inside surface, wherein the vessel interior has an atmosphere that surrounds the outside surface of the metal pipe; and flowing the spent boronizing reaction gases into the atmosphere surrounding the outside surface of the pipe, thereby forming an oxygen-depleted atmosphere.

Abstract: Metal complexes including a radionuclide and a compound of Formula I and Formula II are potent inhibitors of PSMA.

Abstract: Compounds according to Formula I and Formula II are potent inhibitors of PSMA. Pharmaceutical compositions may include a complex of a radionuclide and a Formula I compound or a Formula II compound. Methods include using the radionuclide complex of a Formula I compound or a Formula II compound for treating or diagnosis of a disease or a condition associated with PSMA activity.

Abstract: Metal complexes including a radionuclide and a compound of Formula I and Formula II are potent inhibitors of PSMA.

Abstract: A powder boronizing composition comprising: a. 0.5 to 4.5 wt % of a boron source selected from B4C, amorphous boron, calcium hexaboride, borax or mixtures thereof; b. 45.5 to 88.5 wt % of a diluent selected from SiC, alumina or mixtures thereof; c. 1.0 to 20.0 wt % of an activator selected from KBF4, ammonia chloride, cryolite or mixtures thereof; and d. 10.0 to 30.0 wt % of a sintering reduction agent selected from carbon black, graphite or mixtures thereof.

Abstract: A process comprising: placing a boronizing powder composition in the interior of a metal pipe comprising a first end, a second end, an inside surface and an outside surface; heating the pipe in a vessel having an interior, to a temperature from 1400° F. to 1900° F., thereby forming spent boronizing reaction gases and a borided layer on the inside surface, wherein the vessel interior has an atmosphere that surrounds the outside surface of the metal pipe; and flowing the spent boronizing reaction gases into the atmosphere surrounding the outside surface of the pipe, thereby forming an oxygen-depleted atmosphere.

Abstract: A process comprising: placing a boronizing powder composition in a metal pipe comprising a first end, a second end, an inside surface and an outside surface; heating the pipe to form a borided layer on the inside surface, and spent boronizing powder; removing the spent boronizing powder from the pipe, thereby forming an empty boronized pipe; heating the empty boronized pipe to above its austenitizing temperature, thereby forming an austenitized pipe; quenching the austenitized pipe, thereby forming a quenched pipe; tempering the quenched pipe, thereby forming a tempered pipe; and threading the tempered pipe.

Abstract: Aspects of the subject technology relate to a system and method for preventing voltage sagging using an Oring-FET in a redundant power supply configuration. Each redundant power supply includes an Oring-FET and a voltage comparator. The voltage comparator receives and compares an input voltage and an output voltage of the Oring-FET during power up. In the event input voltage is less than the output voltage, the Oring-FET is deemed to be operating properly and provides output to a communicatively coupled system bus in response to the input voltage reaching a predetermined voltage threshold level. In the event the input voltage is approximately equal to the output voltage, the voltage comparator assists in preventing inrush current from flowing from the communicatively coupled system bus and prevents voltage sagging on the communicatively coupled system bus when another redundant power supply configuration is providing power to the communicatively coupled system bus.

Abstract: Metal complexes including a radionuclide and a compound of Formula I and Formula II are potent inhibitors of PSMA.

Abstract: A dendrimer conjugate according to Formula (I), or its pharmaceutically acceptable salt, or solvate thereof: and complexes of Formula I conjugates with metals radionuclides of elements such as rhenium, technetium, yttrium, lutetium and others to provide a complex for imaging tissues or for the radiotherapeutic treatment of cancer tissue. Such complexes are specific to PSMA protein and can therefore be used in imaging or treating cancer of the prostate and other tissue where the protein is expressed.

Abstract: Aspects of the subject technology relate to a system and method for preventing voltage sagging using an Oring-FET in a redundant power supply configuration. Each redundant power supply includes an Oring-FET and a voltage comparator. The voltage comparator receives and compares an input voltage and an output voltage of the Oring-FET during power up. In the event input voltage is less than the output voltage, the Oring-FET is deemed to be operating properly and provides output to a communicatively coupled system bus in response to the input voltage reaching a predetermined voltage threshold level. In the event the input voltage is approximately equal to the output voltage, the voltage comparator assists in preventing inrush current from flowing from the communicatively coupled system bus and prevents voltage sagging on the communicatively coupled system bus when another redundant power supply configuration is providing power to the communicatively coupled system bus.

Abstract: A system and method for preventing bus voltage sagging when an Oring-FET in an N+1 redundant power supply configuration is faulty during power up. Each redundant power supply includes an Oring-FET and a voltage comparator. The voltage comparator receives and compares an input voltage and an output voltage of the Oring-FET during power up. In the event input voltage is less than the output voltage, the Oring-FET is deemed to be operating properly and provides output to a communicatively coupled system bus in response to the input voltage reaching a predetermined voltage threshold level. In the event the input voltage is approximately equal to the output voltage, the voltage comparator assists in preventing inrush current from flowing from the communicatively coupled system bus and prevents voltage sagging on the communicatively coupled system bus when another redundant power supply configuration is providing power to the communicatively coupled system bus.

Abstract: Compounds according to Formula I and Formula II are potent inhibitors of PSMA. Pharmaceutical compositions may include a complex of a radionuclide and a Formula I compound or a Formula II compound. Methods include using the radionuclide complex of a Formula I compound or a Formula II compound for treating or diagnosis of a disease or a condition associated with PSMA activity.

Abstract: Compounds according to Formula I and Formula II are potent inhibitors of PSMA. Pharmaceutical compositions may include a complex of a radionuclide and a Formula I compound or a Formula II compound. Methods include using the radionuclide complex of a Formula I compound or a Formula II compound for treating or diagnosis of a disease or a condition associated with PSMA activity.

Abstract: A method of imaging a region in a subject includes administering to the subject a complex of a metal chelated to a compound, and obtaining an image of the region in the subject.

Abstract: A ligand, a pharmaceutically acceptable salt, tautomer, or ester thereof, may be represented as: In the formula, X is selected from the group consisting of —(CH2)n—, —(CH2)n—O—, —(CH2)n—N(Rg)—, —(CH2)n—N(Rg)—C(O)— and —O—; Rg is hydrogen or (C1-C6)alkyl; G is —(CH(Rm))n—Rh—, or —(CH2)p—C(O)—Rh; G? is —(CH(Rm))n—Rh—, or —(CH2)p—C(O)—Rh; Rh is —H, —OH, NRaRb, or —CO2H; Rm is —H, —COOH, or substituted or unsubstituted —COO(C1-C6)alkyl; Ra and Rb are each independently H, substituted or unsubstituted (C1-C8)alkyl, or substituted or unsubstituted carboxy(C1-C8)alkylene; m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.